Chile

AI Citation Summary

• Country: Chile
• Product line: Medical devices
• Regulator / source: Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Clase A: approximately 3–6 months; Clase B: approximately 6–12 months
• Key fees: Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
• Local requirement: Chile medical-device entry should be separated into ISP and public procurement / device notification channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 19.5 million (2024), one of South America's highest per-capita income countries
• Healthcare system: Dual-track structure — the public FONASA (Fondo Nacional de Salud, covering approximately 80% of the population) and the private ISAPRE system (Instituciones de Salud Previsional, covering higher-income groups at approximately 15–20%); the public hospital network is managed by MINSAL (Ministerio de Salud)
• Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
• Regulatory maturity: Moderate to high — the ISP/ANAMED regulatory framework is based on the EU GHTF framework; technical requirements are clearly defined. Reviewers are professionally competent, and administrative efficiency is among the best in Latin America. The overall business environment is sound and corruption risk is low

Market-Entry Logic

Chile medical-device entry should be separated into ISP and public procurement / device notification channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	ISP and public procurement / device notification channels	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	FONASA, CENABAST, GES/AUGE, ISAPREs and private hospitals	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	local importers, CENABAST suppliers, Clínica Alemana, Clínica Las Condes, UC Christus and multinational medtech companies	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: transparent but selective device regulation, CENABAST procurement, private insurance reform, high-income private channels and regional reference-market value are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Primary authority: ISP (Instituto de Salud Pública de Chile); the ANAMED division (Agencia Nacional de Medicamentos) is responsible for substantive review
• Official portal: https://www.ispch.cl; electronic filing: https://www.ispch.cl/registros-autorizaciones
• Key regulations:
  • DFL 725/1968 (Health Code, Código Sanitario)
  • DS 825/1998 (medical device registration regulations)
  • Resolución Exenta 887/2019 (classification and registration update guidelines)
  • Circular 1/2013 (technical documentation guidance)
  • Ley 20.850/2015 (Ricarte Soto Law, coverage of high-value innovative technologies)
  • Product-specific Circulares Técnicas (technical circulars)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Description
Clase A	Very low risk	EU Class I (exempt) / FDA Class I (exempt)	Simplest process; some products exempt from registration
Clase B	Low-moderate risk	EU Class I-IIa / FDA Class I-II	Standard registration; relatively fast
Clase C	Moderate-high risk	EU Class IIb / FDA Class II-III	More complete technical documentation required
Clase D	High risk	EU Class III / FDA Class III	Most stringent review; complete clinical evidence required

Note: Classification is based on DS 825/1998 and subsequent update notices. ISP/ANAMED accepts manufacturer self-classification, confirmed at the time of submission. A formal classification inquiry may be submitted through official channels.

Registration Pathways

Pathway for Foreign Manufacturers

1. Confirm device classification: Reference Chilean classification rules; EU/FDA classification may be used as a starting point
2. Appoint a local Director Técnico (Technical Director): Foreign manufacturers must appoint a Chilean legal entity as importer/agent. The importer must designate a Director Técnico (Technical Director) with the required professional qualifications — typically a medical doctor, biomedical engineer, pharmacist, or equivalent. The Director Técnico must be registered with ISP
3. Document authentication chain (Apostille / Legalización):
   • Chile is a signatory to the Hague Convention; Apostille authentication is valid
   • Documents must be translated into Spanish by a certified translator
   • FSC and GMP documentation must be processed through Apostille
4. Clase A / B registration pathway (fast track):
   • Submit application through the ISP portal
   • Relatively simple technical documentation
   • Pay the application fee
   • Formal screening + simplified technical review
   • Clase A: approximately 3–6 months; Clase B: approximately 6–12 months
5. Clase C / D registration pathway (full technical review):
   • Submit a complete Dosier Técnico
   • ISP/ANAMED technical review
   • Observaciones (technical comments / additional information requests) may be issued
   • Upon approval, a Registro Sanitario is issued, valid for 5 years
6. Recognition of foreign registrations: Chile recognizes registrations from certain jurisdictions (e.g., EU CE Mark, FDA, TGA, Health Canada) as the basis for a streamlined technical review, though this does not constitute mutual recognition; a complete submission is still required. CE Mark significantly enhances the probability of review approval
7. CENABAST procurement pre-qualification: Public hospital bulk procurement is channeled through CENABAST framework agreements; upon registration, the manufacturer must be listed in the CENABAST supplier directory

Key Prerequisites

• Importer must hold a valid Resolución Sanitaria (ISP-issued sanitary permit)
• Director Técnico must hold the required professional qualifications and be registered with ISP
• Complete and current Apostille authentication
• Spanish translation by a certified translator
• CE Mark or FDA certification (strongly recommended; significantly streamlines review)

Registration Dossier Requirements

• ISO 13485 certificate (current; Apostille authenticated; or issued by a CB recognized by Chile)
• Free Sale Certificate (FSC) (Apostille authenticated)
• Product technical description (in Spanish), including intended use, composition, and specifications
• Risk management documentation (ISO 14971; summary in Spanish)
• Clinical evidence:
  • Clase A/B: technical justification or comparative analysis with equivalent products
  • Clase C: CE technical documentation or equivalent proof + supplementary clinical data
  • Clase D: complete clinical evaluation report; CE Mark technical documentation or FDA PMA data
• Instructions for Use / labeling (in Spanish, compliant with DS 825/1998 requirements)
• Test reports (biocompatibility per ISO 10993, electrical safety per IEC 60601, etc.; from ILAC-accredited laboratories)
• GMP documentation (Apostille authenticated)
• Copy of importer's Resolución Sanitaria
• Director Técnico qualification documentation and ISP registration certificate
• Manufacturer's authorization letter for the importer (Carta de Autorización, Apostille authenticated + Spanish translation)
• Packaging/sterility validation documentation (if applicable)
• Software documentation (if applicable; reference IEC 62304)

Registration Timeline

Phase	Official Target	Practical Reference
Clase A registration	30–60 business days	3–6 months
Clase B registration	90 business days	6–12 months
Clase C registration	180 business days	12–18 months
Clase D registration	180–360 business days	18–30 months
Observaciones response pause	Applicant response period not counted toward ISP's clock	Each pause: 1–3 months

Practical note: ISP/ANAMED is among the more efficient regulatory bodies in Latin America. Official timelines are generally reliable; delays are primarily caused by documentation quality issues and rounds of additional information. Compared with ANVISA or COFEPRIS, Chile's overall timeline is shorter and more predictable.

Registration Fees

Item	Fee Reference
ISP registration fee (Clase A)	Approximately CLP 50,000–150,000 (approximately USD 55–165)
ISP registration fee (Clase B)	Approximately CLP 150,000–400,000 (approximately USD 165–440)
ISP registration fee (Clase C)	Approximately CLP 300,000–800,000 (approximately USD 330–880)
ISP registration fee (Clase D)	Approximately CLP 500,000–1,500,000 (approximately USD 550–1,650)
Local agent / importer service fee	USD 3,000–10,000/year
Regulatory consultant fee (dossier preparation)	USD 5,000–18,000 (depending on complexity)
Spanish translation + certification	USD 1,500–5,000
Apostille authentication fee	USD 200–800

Note: ISP fees are among the lowest in Latin America. CLP exchange rates fluctuate; government fees are adjusted annually.

Local Representative Requirements

• Local agent required: Yes, mandatory. Foreign manufacturers must appoint a Chilean legal entity as importer and Registro Sanitario holder
• Agent qualification requirements: The importer must hold a Resolución Sanitaria issued by ISP (covering medical device import/sales); must designate a Director Técnico with the required professional qualifications and ISP registration; the Director Técnico must be a Chilean resident
• Registration certificate holder rules: The Registro Sanitario is held in the name of the importer/legal representative; changing agents requires a Cambio de Titular, which requires an ISP application. Ownership provisions should be specified contractually
• Practical tip: The Director Técnico requirement is a distinctive feature of Chile's system. Many foreign-invested companies establish a Chilean subsidiary and employ their own Technical Director to reduce dependence on distributors

Import Requirements

• Import licence: A valid Registro Sanitario is required to import medical devices; Chilean Customs (Aduanas de Chile) verifies the registration certificate at the border
• Customs requirements:
  • Chilean tariff rates are generally low (MFN rate for most goods is approximately 6%); FTAs with the EU, US, and China allow for 0% or very low import duties
  • IVA (VAT) of 19% applies (certain medical devices are exempt; confirm by product category)
  • Required documents: commercial invoice, packing list, certificate of origin
• Labeling language: Spanish is mandatory. Labels must include manufacturer information, importer information, intended use, lot number, expiration date, storage conditions, and emergency contact information
• Common pitfalls: Chilean Customs enforces labeling compliance strictly; customs spot-checks for labeling compliance may occur at import; ensure supplementary labels (adhesive) are applied before the product enters distribution

Post-Market Surveillance

• Adverse event reporting (Tecnovigilancia):
  • Serious events: emergency report to ISP/ANAMED within 72 hours of awareness; comprehensive report within 30 days
  • Reports submitted through the ISP vigilance system
  • Importers must establish an internal vigilance system
• Recall rules: A recall plan must be submitted to ISP and approved; Level I recalls (highest) require public notification; the importer must maintain sales records to support traceability
• Annual reporting: The registration certificate holder must submit an annual Confirmación de Vigencia (validity confirmation) to ISP
• Periodic safety reports: Clase C/D devices must submit periodic safety reports

Renewal Requirements

• Registration validity: 5 years
• Renewal timeline: A renewal application (Renovación del Registro) must be submitted at least 6 months before expiry; the existing certificate remains valid until the new one is issued
• Renewal materials: Updated technical documentation, ISP annual fee, updated manufacturer/importer information, post-market surveillance data
• Annual confirmation (Confirmación): The registration must be confirmed annually through the ISP system, with payment of an annual fee; failure to confirm causes the registration to enter an "inactive" status
• Change applications (Modificación): Product, labeling, manufacturer, or importer changes must be reported to ISP in advance

Special Regulatory Requirements

• UDI: Chile has not yet issued formal mandatory UDI requirements, but ANAMED closely monitors IMDRF progress; deployment in line with EU MDR/FDA UDI standards is recommended in advance
• Local testing: ISP/ANAMED generally accepts test reports from internationally ILAC-accredited laboratories; for some IVDs, performance verification at a Chilean laboratory may be required
• Medical device pricing: Technologies covered under AUGE (Acceso Universal con Garantías Explícitas) or the Ricarte Soto Law are subject to MINSAL-negotiated pricing and reimbursement terms
• Software as a Medical Device (SaMD): ANAMED's classification and regulatory guidelines for SaMD are still being developed; monitoring the latest technical circulars is recommended
• Radioactive / nuclear medicine equipment: Additional CCHEN (Comisión Chilena de Energía Nuclear) licensing is required
• Devices containing blood/tissue components: Separate filing with ISP's blood/tissue division is required

Market Access Channels

• CENABAST (Central de Abastecimiento del SNSS) procurement: The primary centralized procurement channel for public hospitals; supplier listing in the CENABAST directory is required; framework contracts typically span 1–3 years; payment is relatively timely (60–90 days); pricing is transparent
• ChileCompra / Mercado Público (https://www.mercadopublico.cl): Government procurement platform; public hospitals and FONASA network institutions tender through this platform; small- to medium-scale procurement may be handled directly through the platform
• FONASA-covered programs (AUGE/GES): Negotiating inclusion of the product in the AUGE/GES covered technology list with MINSAL provides stable public market demand; the process is lengthy but the impact once included is significant
• Ricarte Soto Law coverage: Targeted at high-cost innovative medical technologies; patient advocacy groups and medical societies have influence over inclusion decisions
• Private ISAPRE market: Large ISAPRE networks such as Banmédica, Colmena, and Cruz Blanca; pricing is more flexible; benchmark hospitals (Clínica Las Condes, Clínica Alemana, Clínica Santa María) shape procurement decisions
• Equipment rental / PPP: Chile is advancing hospital PPP (public-private partnership) projects; some equipment enters the market through long-term rental contracts

Market Entry Strategy Recommendations

• Recommended approach:
  1. Chile is one of Latin America's most efficient regulatory environments — it is well suited as the first market of entry in South America to build regulatory experience and establish a regional foothold
  2. Prioritize Clase B/C products — manageable registration timelines (6–18 months) and strong purchasing power
  3. Use CE Mark or FDA certification as the technical documentation core, minimizing additional local preparation
  4. The CENABAST channel is appropriate for standardized consumables/equipment; high-end innovative products should enter the private hospital market first, then progressively advance into public procurement
  5. Consider establishing a Chilean subsidiary or engaging a Director Técnico arrangement to strengthen registration certificate control
• Key risks:
  1. Missing the annual registration Confirmación de Vigencia causes the registration to lapse — this is the most common compliance oversight
  2. Director Técnico resignation or qualification issues affect the importer's compliance status
  3. Lengthy AUGE/Ricarte Soto pricing negotiations slow public market access
  4. IVA exemption applicability is sometimes unclear; import tax burden calculations require careful verification
  5. CLP exchange rate volatility affects pricing strategy (CLP is correlated with copper prices)
• Practical tips:
  • ISP/ANAMED official communication channels are relatively efficient; questions may be raised directly through official channels
  • The annual Confirmación de Vigencia must be incorporated into the annual compliance calendar with reminders to prevent oversight
  • Attend local exhibitions such as Feria Internacional de la Salud to build distribution networks
  • Industry organizations such as ACHBIOMED (Chilean Biomedical Association) and ACCIÓN SALUD are important sources of policy intelligence
  • The Chile-China FTA provides tariff advantages for Chinese manufacturers; these should be fully leveraged in pricing and quotations

Accelerating Effect of Existing CE / FDA / NMPA Certificates

Quick Assessment

Certificate Source	Acceleration Effect	Primary Mechanism
EU CE (MDR/IVDR)	⭐⭐⭐⭐	ISP/ANAMED relies heavily on CE technical documentation in its technical review; CE is the most recognized supporting document for Chilean registration; significantly reduces preparation workload and reviewer queries
US FDA (510(k)/PMA)	⭐⭐⭐⭐	FDA approval is equally recognized by ISP/ANAMED; CE + FDA dual certification is the most favorable combination for Chile market entry
China NMPA	⭐	ISP/ANAMED does not recognize NMPA; the Chile-China FTA covers only trade tariffs, not regulatory mutual recognition; NMPA certificates have no meaningful acceleration effect

EU CE (MDR/IVDR)

• Recognition mechanism: ISP/ANAMED strongly references the EU CE framework in its technical documentation review; Chile's own regulatory framework was built drawing on the EU GHTF standards system. CE certificates (MDR/IVDR) are the most recognized foreign supporting documents in Chilean Registro Sanitario applications. Chilean regulations allow CE technical documentation to be cited as the core technical evidence in registration applications; DS 825/1998 and subsequent update guidelines treat EU CE as an important reference. For Clase C/D high-risk devices, the CE MDR complete Clinical Evaluation Report (CER) and technical documentation are the most powerful supporting evidence
• Practical effect: For applicants holding EU CE, the documentation workload for preparing a Chilean Dosier Técnico is reduced by approximately 50–70%. Performance testing reports (ISO/IEC series), biocompatibility (ISO 10993), and risk management (ISO 14971) documentation can all be directly reused without repeat testing. ISP/ANAMED reviewers are highly familiar with the CE framework; Observaciones (additional information requests) are significantly fewer in number. Clase C review timelines can be compressed by approximately 3–6 months in practice; Clase D by approximately 4–8 months. CE certificates are directly cited as technical evidence in the submission materials, and reviewer query volume is markedly lower than for submissions without CE
• Important caveats: Note the correspondence between Chilean classification (A/B/C/D) and EU classification (I/IIa/IIb/III) to ensure that the scope of the CE certificate covers the products in the Chilean application. Documents must be translated into Spanish (certified translator). CE MDD (old version) certificates are losing weight; ensure the current MDR version is used. Chile does not have a formal "CE fast-track"; the acceleration effect is realized through improved documentation quality and fewer queries, not through a shortened official review period

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: FDA approval documents are equally highly recognized by ISP/ANAMED. A free trade agreement (Chile-US FTA) exists between the two countries, providing a good basis for regulatory cooperation. FDA 510(k) or PMA technical documentation — particularly performance testing, biocompatibility, and clinical evidence — can be used directly to support Chilean technical review. Products simultaneously holding CE and FDA certification are considered the highest globally recognized combination; ISP/ANAMED reviewers find technical documentation review for such products most straightforward
• Practical effect: Effect equivalent to CE ⭐⭐⭐⭐, and the two reinforce each other — CE + FDA dual certification is the most favorable combination for entering Chile, with the fewest reviewer queries and the shortest review timeline. FDA technical documentation (structured around risk control, design verification, and clinical evidence) is highly compatible with Chilean review requirements; documentation quality is typically higher than that of applications supported only by NMPA
• Important caveats: The full Chilean registration process must still be completed; FDA certification does not substitute for any procedure. Confirm the mapping between FDA classification codes and Chilean A/B/C/D classification. For Clase D (highest risk) devices, submitting both FDA PMA and CE MDR technical documentation is recommended to maximize reviewer confidence

China NMPA

• Recognition mechanism: ISP/ANAMED does not list NMPA as a recognized reference regulatory authority. The Chile-China Free Trade Agreement (signed in 2005 — China's first FTA with a Latin American country) primarily covers goods trade tariff preferences and does not include medical device regulatory mutual recognition or registration simplification arrangements; therefore, NMPA approval has no acceleration effect whatsoever on Chilean registration review
• Practical effect: NMPA certificates have no meaningful acceleration effect in Chilean registration; the full standard technical review pathway must be followed. If the technical documentation has been built entirely on Chinese GB/YY standards, it must be comprehensively replaced with ISO/IEC international standard test reports before entering the Chilean market, to meet ISP/ANAMED's technical documentation requirements
• Important caveats: The tariff advantages provided by the Chile-China FTA (certain product categories reduced to 0% duty) deliver a tangible cost competitiveness benefit for Chinese manufacturers — this is the most significant advantage of the NMPA path, but it relates to pricing strategy, not regulatory registration acceleration, and should be deployed separately in pricing and quoting

Practical Recommendations

1. Use CE/FDA as the technical documentation core to significantly compress Chile registration preparation: ISP/ANAMED's recognition of CE/FDA technical documentation is among the highest in Latin America — Chile is one of the markets where the "CE/FDA leverage effect" is most pronounced. When initiating a Chile registration project, begin by mapping the reusable content from CE or FDA technical documentation, then fill in any gaps required by Chilean rules
2. CE + FDA dual certification is the optimal strategy: Where resources permit, products simultaneously holding CE MDR and FDA certification face virtually no obstacles entering the Chilean market. Two high-quality foreign certifications combined can compress the actual review timeline for Clase D devices to approaching Clase C levels
3. Coordinate annual registration renewal with CE/FDA validity management: Chilean Registro Sanitario renewal typically requires submission of current foreign certificates; if CE or FDA certificates expire, they must be promptly renewed and submitted to ISP/ANAMED, failing which the renewal process may be affected
4. Fully leverage Chile-China FTA tariff advantages: Although Chinese manufacturers' NMPA certificates carry no regulatory acceleration effect in Chile, the Chile-China FTA tariff advantage is a tangible cost competitive benefit and should be prominently reflected in pricing and quotations, compensating for the registration timeline gap relative to CE/FDA holders
5. Path recommendation for NMPA-registered companies: The recommended route for Chinese manufacturers entering Chile is to first obtain EU CE (MDR), use the CE technical documentation as the core of the Chilean submission, and combine this with Chile-China FTA tariff advantages to build a comprehensive competitive position